PSP Research LLC
In its 13F for Q1 2026 (holdings as of March 31, 2026, filed April 17, 2026), PSP Research LLC reported 79 stock positions worth $141.3 million. Its top holding was iShares 0-3 Month Treasury B (SGOV) at 49.9% of the portfolio, followed by SS SPDR S&P Biotech ETF (XBI, 25.7%) and Sera Prognostics Class A (SERA, 3.4%). Compared with Q4 2025, it opened 20 new positions, sold out of 26, added to 10 and reduced 43. The biggest buy was a new position in SS SPDR S&P Biotech ETF (XBI) and the biggest sale an exit from Travere Therapeutics (TVTX).
- Most Recent 13F
- Q2 2026
- Location
- LAS VEGAS, NV
- CIK
- 0002106939
- Portfolio Value
- $141.3M (Q1 2026)
- SEC Filing
- 0001951757-26-000630 ↗ filed Apr 17, 2026
Holdings Value
Holdings 79 stocks · $141.3M
| SGOV iShares 0-3 Month Treasury B | 49.86% | 700,000 | $70.5M | No change |
| XBI SS SPDR S&P Biotech ETF | 25.75% | 284,900 | $36.4M | New |
| SERA Sera Prognostics Inc. Class A | 3.44% | 2,396,685 | $4.9M | New |
| DFTX Definium Therapeutics Inc. | 0.47% | 34,800 | $658K | Reduce -0.1% |
| TYRA Tyra Biosciences Inc. | 0.43% | 16,000 | $613K | Reduce -26.8% |
| ASND Ascendis Pharma A/S | 0.40% | 2,500 | $572K | Reduce -3.1% |
| PHVS Pharvaris NV | 0.40% | 20,000 | $565K | Reduce -2.5% |
| CYTK Cytokinetics Inc. | 0.39% | 8,300 | $547K | Reduce -0.2% |
| RPRX Royalty Pharma PLC Class A | 0.37% | 11,000 | $528K | Reduce -20.4% |
| KYMR Kymera Therapeutics Inc. | 0.37% | 6,300 | $525K | Reduce -0.8% |
| HALO Halozyme Therapeutics Inc. | 0.37% | 8,026 | $519K | No change |
| EXEL Exelixis Inc. | 0.36% | 11,948 | $512K | No change |
| IRON Disc Medicine Inc. | 0.36% | 8,000 | $512K | New |
| IONS Ionis Pharmaceuticals Inc. | 0.36% | 6,800 | $511K | No change |
| AGIO Agios Pharmaceuticals Inc. | 0.36% | 15,000 | $507K | New |
| NBIX Neurocrine Biosciences Inc. | 0.36% | 3,848 | $507K | Add +3.0% |
| INCY Incyte Corp. | 0.35% | 5,300 | $499K | Reduce -0.9% |
| TARS Tarsus Pharmaceuticals Inc. | 0.35% | 7,000 | $491K | Add +7.4% |
| VKTX Viking Therapeutics Inc. | 0.35% | 15,000 | $488K | Add +1.9% |
| ALNY Alnylam Pharmaceuticals Inc. | 0.34% | 1,465 | $485K | Add +11.2% |
| PRAX Praxis Precision Medicines I | 0.34% | 1,500 | $483K | Reduce -24.3% |
| AXSM Axsome Therapeutics Inc. | 0.34% | 2,845 | $481K | New |
| NAMS Newamsterdam Pharma Co. NV | 0.34% | 15,000 | $480K | Add +0.5% |
| ARDX Ardelyx Inc. | 0.34% | 80,000 | $479K | New |
| IMVT Immunovant Inc. | 0.34% | 19,200 | $477K | Reduce -5.4% |
| ARGX Argenx SE - ADR | 0.33% | 641 | $468K | Add +1.8% |
| SNDX Syndax Pharmaceuticals Inc. | 0.33% | 20,000 | $467K | Reduce -19.1% |
| INBX Inhibrx Biosciences Inc. | 0.33% | 6,927 | $466K | Add +8.4% |
| ARQT Arcutis Biotherapeutics Inc. | 0.33% | 19,700 | $464K | Add +5.3% |
| RARE Ultragenyx Pharmaceutical Inc. | 0.33% | 22,100 | $463K | New |
| MIRM Mirum Pharmaceuticals Inc. | 0.33% | 5,000 | $462K | Reduce -27.1% |
| COGT Cogent Biosciences Inc. | 0.33% | 12,000 | $462K | Reduce -9.3% |
| GLUE Monte Rosa Therapeutics Inc. | 0.33% | 28,000 | $461K | New |
| IMCR Immunocore Holdings PLC-ADR | 0.32% | 15,141 | $457K | Add +5.0% |
| CRSP Crispr Therapeutics AG | 0.32% | 9,500 | $452K | Reduce -0.8% |
| BBIO Bridgebio Pharma Inc. | 0.32% | 6,000 | $446K | Reduce -16.0% |
| NRIX Nurix Therapeutics Inc. | 0.31% | 28,700 | $445K | Reduce -0.1% |
| AUPH Aurinia Pharmaceuticals Inc. | 0.31% | 30,000 | $445K | Reduce -11.6% |
| ACAD Acadia Pharmaceuticals Inc. | 0.31% | 19,766 | $440K | No change |
| RAPP Rapport Therapeutics Inc. | 0.31% | 14,000 | $438K | Reduce -20.0% |
| IMNM Immunome Inc. | 0.31% | 20,000 | $437K | Reduce -20.8% |
| KNSA Kiniksa Pharmaceuticals Inte | 0.31% | 9,000 | $433K | Reduce -28.9% |
| TGTX TG Therapeutics Inc. | 0.31% | 13,000 | $432K | Reduce -27.0% |
| DNTH Dianthus Therapeutics Inc. | 0.30% | 5,000 | $420K | Reduce -60.7% |
| CLDX Celldex Therapeutics Inc. | 0.29% | 13,000 | $412K | Reduce -36.2% |
| PTCT PTC Therapeutics Inc. | 0.29% | 6,000 | $409K | Reduce -14.8% |
| VERA Vera Therapeutics Inc. | 0.28% | 10,000 | $402K | Add +0.0% |
| HRMY Harmony Biosciences Holdings | 0.28% | 14,283 | $400K | No change |
| CRNX Crinetics Pharmaceuticals Inc. | 0.28% | 11,000 | $400K | Reduce -2.8% |
| CMPS Compass Pathways PLC | 0.28% | 71,000 | $393K | New |
| STOK Stoke Therapeutics Inc. | 0.28% | 12,000 | $391K | Reduce -27.8% |
| KOD Kodiak Sciences Inc. | 0.27% | 10,000 | $381K | Reduce -48.5% |
| DYN Dyne Therapeutics Inc. | 0.26% | 20,000 | $363K | Reduce -7.1% |
| TRVI Trevi Therapeutics Inc. | 0.25% | 30,000 | $358K | New |
| NTLA Intellia Therapeutics Inc. | 0.24% | 26,900 | $345K | New |
| PTGX Protagonist Therapeutics Inc. | 0.22% | 3,000 | $316K | Reduce -51.0% |
| MDGL Madrigal Pharmaceuticals Inc. | 0.22% | 600 | $314K | Reduce -32.7% |
| SUPN Supernus Pharmaceuticals Inc. | 0.22% | 6,000 | $310K | Reduce -44.2% |
| TNGX Tango Therapeutics Inc. | 0.21% | 14,400 | $301K | New |
| ERAS Erasca Inc. | 0.20% | 17,327 | $280K | New |
| ELVN Enliven Therapeutics Inc. | 0.19% | 7,000 | $274K | New |
| SYRE Spyre Therapeutics Inc. | 0.18% | 5,159 | $260K | Reduce -67.4% |
| ZYME Zymeworks Inc. | 0.18% | 10,000 | $250K | Reduce -50.8% |
| XENE Xenon Pharmaceuticals Inc. | 0.17% | 4,200 | $244K | Reduce -64.0% |
| ORKA Oruka Therapeutics Inc. | 0.17% | 4,968 | $244K | New |
| CELC Celcuity Inc. | 0.16% | 2,000 | $228K | Reduce -61.9% |
| KALV Kalvista Pharmaceuticals Inc. | 0.15% | 10,795 | $217K | New |
| LEGN Legend Biotech Corp.-ADR | 0.15% | 12,000 | $217K | Reduce -50.8% |
| ALKS Alkermes PLC | 0.15% | 6,000 | $212K | Reduce -68.9% |
| APGE Apogee Therapeutics Inc. | 0.15% | 2,500 | $210K | Reduce -64.2% |
| UTHR United Therapeutics Corp. | 0.15% | 350 | $208K | Reduce -67.6% |
| EWTX Edgewise Therapeutics Inc. | 0.14% | 6,500 | $205K | New |
| SMMT Summit Therapeutics Inc. | 0.14% | 10,223 | $194K | New |
| ORIC Oric Pharmaceuticals Inc. | 0.12% | 13,000 | $165K | New |
| CMPX Compass Therapeutics Inc. | 0.11% | 30,000 | $159K | New |
| AMLX Amylyx Pharmaceuticals Inc. | 0.11% | 10,838 | $151K | Reduce -75.5% |
| OLMA Olema Pharmaceuticals Inc. | 0.11% | 10,000 | $149K | Reduce -47.5% |
| EYPT Eyepoint Inc. | 0.09% | 10,000 | $129K | Reduce -66.1% |
| OCUL Ocular Therapeutix Inc. | 0.09% | 15,000 | $127K | Reduce -65.0% |
Portfolio Sells Q4 2025 → Q1 2026
| TVTX Travere Therapeutics Inc. | Sold out | 0.00% | −0.51 |
| JAZZ Jazz Pharmaceuticals PLC | Sold out | 0.00% | −0.48 |
| CGON CG Oncology Inc. | Sold out | 0.00% | −0.48 |
| BLTE Belite Bio Inc. - ADR | Sold out | 0.00% | −0.48 |
| APLS Apellis Pharmaceuticals Inc. | Sold out | 0.00% | −0.48 |
| TERN Terns Pharmaceuticals Inc. | Sold out | 0.00% | −0.48 |
| RVMD Revolution Medicines Inc. | Sold out | 0.00% | −0.48 |
| CNTA Centessa Pharmaceuticals Ltd. | Sold out | 0.00% | −0.48 |
| MLYS Mineralys Therapeutics Inc. | Sold out | 0.00% | −0.47 |
| ACLX Arcellx Inc. | Sold out | 0.00% | −0.47 |
| ROIV Roivant Sciences Ltd. | Sold out | 0.00% | −0.47 |
| LQDA Liquidia Corp. | Sold out | 0.00% | −0.47 |
| PVLA Palvella Therapeutics Inc. | Sold out | 0.00% | −0.47 |
| INSM Insmed Inc. | Sold out | 0.00% | −0.46 |
| NUVL Nuvalent Inc. Class A | Sold out | 0.00% | −0.46 |
| VRDN Viridian Therapeutics Inc. | Sold out | 0.00% | −0.46 |
| WVE Wave Life Sciences Ltd. | Sold out | 0.00% | −0.46 |
| MAZE Maze Therapeutics Inc. | Sold out | 0.00% | −0.46 |
| DNLI Denali Therapeutics Inc. | Sold out | 0.00% | −0.46 |
| BMRN Biomarin Pharmaceutical Inc. | Sold out | 0.00% | −0.46 |
| BEAM Beam Therapeutics Inc. | Sold out | 0.00% | −0.44 |
| RYTM Rhythm Pharmaceuticals Inc. | Sold out | 0.00% | −0.44 |
| UPB Upstream Bio Inc. | Sold out | 0.00% | −0.42 |
| GPCR Structure Therapeutics Inc. | Sold out | 0.00% | −0.41 |
| ARWR Arrowhead Pharmaceuticals Inc. | Sold out | 0.00% | −0.39 |
| EYPT Eyepoint Inc. | Reduce -66.1% | 0.09% | −0.38 |
| ALMS Alumis Inc. | Sold out | 0.00% | −0.37 |
| OCUL Ocular Therapeutix Inc. | Reduce -65.0% | 0.09% | −0.36 |
| AMLX Amylyx Pharmaceuticals Inc. | Reduce -75.5% | 0.11% | −0.36 |
| ALKS Alkermes PLC | Reduce -68.9% | 0.15% | −0.32 |
| UTHR United Therapeutics Corp. | Reduce -67.6% | 0.15% | −0.31 |
| APGE Apogee Therapeutics Inc. | Reduce -64.2% | 0.15% | −0.31 |
| OLMA Olema Pharmaceuticals Inc. | Reduce -47.5% | 0.11% | −0.31 |
| LEGN Legend Biotech Corp.-ADR | Reduce -50.8% | 0.15% | −0.31 |
| CELC Celcuity Inc. | Reduce -61.9% | 0.16% | −0.30 |
| ZYME Zymeworks Inc. | Reduce -50.8% | 0.18% | −0.29 |
| XENE Xenon Pharmaceuticals Inc. | Reduce -64.0% | 0.17% | −0.28 |
| SYRE Spyre Therapeutics Inc. | Reduce -67.4% | 0.18% | −0.27 |
| SUPN Supernus Pharmaceuticals Inc. | Reduce -44.2% | 0.22% | −0.25 |
| PTGX Protagonist Therapeutics Inc. | Reduce -51.0% | 0.22% | −0.24 |
| MDGL Madrigal Pharmaceuticals Inc. | Reduce -32.7% | 0.22% | −0.23 |
| KOD Kodiak Sciences Inc. | Reduce -48.5% | 0.27% | −0.20 |
| CLDX Celldex Therapeutics Inc. | Reduce -36.2% | 0.29% | −0.19 |
| STOK Stoke Therapeutics Inc. | Reduce -27.8% | 0.28% | −0.18 |
| PTCT PTC Therapeutics Inc. | Reduce -14.8% | 0.29% | −0.18 |
| CRNX Crinetics Pharmaceuticals Inc. | Reduce -2.8% | 0.28% | −0.18 |
| PRAX Praxis Precision Medicines I | Reduce -24.3% | 0.34% | −0.17 |
| IMNM Immunome Inc. | Reduce -20.8% | 0.31% | −0.16 |
| BBIO Bridgebio Pharma Inc. | Reduce -16.0% | 0.32% | −0.16 |
| DNTH Dianthus Therapeutics Inc. | Reduce -60.7% | 0.30% | −0.16 |
Portfolio Buys Q4 2025 → Q1 2026
| XBI SS SPDR S&P Biotech ETF | New | 25.75% | +25.75 |
| SERA Sera Prognostics Inc. Class A | New | 3.44% | +3.44 |
| IRON Disc Medicine Inc. | New | 0.36% | +0.36 |
| AGIO Agios Pharmaceuticals Inc. | New | 0.36% | +0.36 |
| AXSM Axsome Therapeutics Inc. | New | 0.34% | +0.34 |
| ARDX Ardelyx Inc. | New | 0.34% | +0.34 |
| RARE Ultragenyx Pharmaceutical Inc. | New | 0.33% | +0.33 |
| GLUE Monte Rosa Therapeutics Inc. | New | 0.33% | +0.33 |
| CMPS Compass Pathways PLC | New | 0.28% | +0.28 |
| TRVI Trevi Therapeutics Inc. | New | 0.25% | +0.25 |
| NTLA Intellia Therapeutics Inc. | New | 0.24% | +0.24 |
| TNGX Tango Therapeutics Inc. | New | 0.21% | +0.21 |
| ERAS Erasca Inc. | New | 0.20% | +0.20 |
| ELVN Enliven Therapeutics Inc. | New | 0.19% | +0.19 |
| ORKA Oruka Therapeutics Inc. | New | 0.17% | +0.17 |
| KALV Kalvista Pharmaceuticals Inc. | New | 0.15% | +0.15 |
| EWTX Edgewise Therapeutics Inc. | New | 0.14% | +0.14 |
| SMMT Summit Therapeutics Inc. | New | 0.14% | +0.14 |
| ORIC Oric Pharmaceuticals Inc. | New | 0.12% | +0.12 |
| CMPX Compass Therapeutics Inc. | New | 0.11% | +0.11 |
| NBIX Neurocrine Biosciences Inc. | Add +3.0% | 0.36% | −0.10 |
| VKTX Viking Therapeutics Inc. | Add +1.9% | 0.35% | −0.11 |
| INBX Inhibrx Biosciences Inc. | Add +8.4% | 0.33% | −0.11 |
| IMCR Immunocore Holdings PLC-ADR | Add +5.0% | 0.32% | −0.11 |
| ALNY Alnylam Pharmaceuticals Inc. | Add +11.2% | 0.34% | −0.12 |
| NAMS Newamsterdam Pharma Co. NV | Add +0.5% | 0.34% | −0.12 |
| TARS Tarsus Pharmaceuticals Inc. | Add +7.4% | 0.35% | −0.12 |
| ARGX Argenx SE - ADR | Add +1.8% | 0.33% | −0.13 |
| ARQT Arcutis Biotherapeutics Inc. | Add +5.3% | 0.33% | −0.15 |
| VERA Vera Therapeutics Inc. | Add +0.0% | 0.28% | −0.16 |